November 18, 2026

Remedy Robotics Raises $62 Million: How AI-Powered Surgical Robots Could Transform the Future of Stroke Treatment


Remedy Robotics Raises $62 Million: How AI-Powered Surgical Robots Could Transform the Future of Stroke Treatment

Hookline: What if life-saving surgery no longer depended on how close a patient lived to a specialist? With a $62 million investment, Remedy Robotics is working to bring advanced robotic medical intervention beyond traditional hospital boundaries.

The healthcare industry is experiencing a major technological transformation as artificial intelligence, robotics, and advanced medical engineering create new possibilities for patient care. Among the emerging companies driving this change is Remedy Robotics, a San Francisco-based medical technology startup developing AI-powered robotic systems for cardiovascular treatment.

The company recently secured $62 million in Series B funding, marking a significant milestone in its mission to make specialized medical procedures more accessible. Its flagship innovation, the N1 System, is designed to help physicians perform complex endovascular procedures through robotic technology, including remote operation.

With growing investor confidence and an expanding network of healthcare partners, Remedy Robotics is positioning itself at the intersection of artificial intelligence, medical robotics, and next-generation healthcare.

$62 Million Series B Funding: Investors Back the Future of Medical Robotics

On November 16, 2026, Remedy Robotics announced that it had raised $62 million in a Series B funding round led by DCVC, a venture capital firm specializing in deep technology investments.

The funding round also attracted several new investors, including UC Investments, Skip Capital, and Hostplus. Existing investors, including Blackbird, Build Collective by Tony Fadell, Divergent Capital, and KdT Ventures, also participated.

The company plans to use the newly raised capital to accelerate several important milestones:

  • Support a planned pivotal clinical trial in partnership with the University of California.
  • Advance the N1 System towards US Food and Drug Administration (FDA) approval for neurovascular intervention.
  • Deploy additional prototype systems across its clinical partner network.
  • Improve artificial intelligence capabilities and develop advanced autonomous functions.

The investment represents a significant vote of confidence in Remedy Robotics’ technology and its potential to address major challenges in global healthcare.

About Remedy Robotics: Bringing Specialized Healthcare Beyond Hospital Boundaries

Founded in 2021, Remedy Robotics was established to address a critical challenge in modern medicine: limited access to specialized cardiovascular treatment.

The company was co-founded by Dr. David Bell (CEO) and Dr. Jake Sganga (CTO). Their vision combines medical expertise, engineering, robotics, and artificial intelligence to develop advanced solutions for endovascular procedures.

Endovascular intervention involves treating conditions affecting blood vessels using minimally invasive techniques. These procedures are particularly important in treating certain types of stroke and other cardiovascular emergencies.

However, access to these treatments remains limited because only a relatively small number of hospitals have the specialized equipment and experienced physicians required.

Remedy Robotics aims to reduce this geographical barrier by developing robotic systems that could allow specialists to perform procedures remotely, potentially connecting experienced medical professionals with patients in underserved locations.

According to the company, fewer than 3% of eligible stroke patients worldwide currently receive timely access to endovascular intervention.

N1 System: The Technology Driving Remedy Robotics

At the centre of Remedy Robotics’ innovation is its N1 System, an AI-enabled robotic platform and software suite designed for endovascular intervention.

The system combines advanced robotics, machine learning, and computer vision to support physicians during complex procedures.

Its key capabilities include:

1. AI-Powered Medical Imaging

The platform uses machine learning to analyse preoperative medical images and help specialists prepare for procedures before treatment begins.

2. Robotic Instrument Control

The robotic platform is designed to control specialized medical instruments, including catheters and guidewires, with precision during endovascular procedures.

3. Remote Medical Intervention

One of its most promising capabilities is remote operation. The technology is designed to allow specialists to control robotic instruments from a different location, potentially extending specialist expertise to hospitals that lack on-site specialists.

4. Advanced Image Registration

The system provides real-time 3D-to-2D image registration, helping physicians align different imaging views during medical procedures.

5. Development of Autonomous Functions

Remedy is also advancing additional automation capabilities, with the long-term goal of enabling greater autonomy in robotic medical procedures.

Together, these technologies aim to improve procedural control and expand access to specialized cardiovascular treatment.

Recent Developments: Important Milestones During 2026

Remedy Robotics has continued building its industry presence through technology development, healthcare partnerships, and engagement with the medical and AI communities.

Some notable developments from the last three months include:

September 15, 2026 – AI and Healthcare Industry Participation

CEO Dr. David Bell participated in the AI Inside the Health System panel at Imagination in Action in Silicon Valley. The appearance highlighted the company’s involvement in discussions about artificial intelligence and its growing role in healthcare systems.

October 7, 2026 – Founder Shares Insights on Wild Hearts Podcast

Dr. David Bell appeared on the Wild Hearts Podcast, providing another opportunity to discuss the company’s work and its vision for the future of medical technology.

November 16, 2026 – Major Series B Funding Announcement

The company announced its $62 million Series B funding round led by DCVC. This capital is expected to support clinical trials, regulatory progress, prototype deployment, and further development of the N1 System.

These developments demonstrate Remedy Robotics’ continued efforts to strengthen its position in the emerging medical robotics industry.

Clinical Milestones and Global Healthcare Partnerships

Remedy Robotics has already achieved important technological milestones.

In December 2024, the company reported completing its first-in-human clinical procedures. In October 2025, it announced the successful completion of what it described as the world’s first fully remote neurointerventional procedures using the N1 System.

The company has also established strategic relationships with organizations including the University of California, SVIN Mission Thrombectomy, and the Australian Stroke Alliance.

According to DCVC, Remedy currently works with more than 100 hospitals worldwide.

These relationships are important as the company moves towards larger clinical studies and potential regulatory approval.

Future Growth: What Lies Ahead for Remedy Robotics?

With fresh funding and growing industry interest, Remedy Robotics is entering an important stage of development.

Its immediate priorities include advancing the N1 System through clinical trials, progressing towards FDA approval, and expanding prototype deployments across its healthcare partner network.

Beyond neurovascular procedures, the company’s technology has potential applications in coronary and peripheral vascular interventions.

However, the company must still demonstrate safety and effectiveness through appropriate clinical evaluation and meet regulatory requirements before commercial deployment.

The successful completion of these milestones could create new opportunities for robotic-assisted healthcare and remote medical intervention.

Conclusion: A New Chapter in AI-Powered Healthcare

Remedy Robotics represents an exciting development in the growing intersection of artificial intelligence and medical robotics.

Its $62 million Series B funding round reflects investor interest in technologies that address real-world healthcare challenges rather than simply introducing incremental improvements.

Although the N1 System remains investigational, its potential to connect medical specialists with patients across geographical boundaries makes the company’s vision particularly significant.

As healthcare systems continue exploring advanced technologies, Remedy Robotics could become an important contributor to the future of cardiovascular treatment.

The next major breakthrough in healthcare may not simply be a better surgical instrument. It could be a technology that makes expert medical care accessible, regardless of distance.                                                                                                                                                                                                                                        Written By                                                                                                                                                                                                        Usha

Leave a Reply

Your email address will not be published. Required fields are marked *